Basilea Pharmaceutica AG provided earnings guidance for the year 2024. For the year, the company's total revenue is expected to amount to approximately CHF 183 million. The company expects a more than 50% increase in operating profit to approximately CHF 30 million and a more than doubling of net profit to approximately CHF 25 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
42.78 CHF | -1.55% | -0.46% | +21.95% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.95% | 576M | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+37.09% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- BSLN Stock
- News Basilea Pharmaceutica AG
- Basilea Pharmaceutica AG Provides Earnings Guidance for the Year 2024